Latest Structure Therapeutics News & Updates

See the latest news and media coverage for Structure. We track all announcements, press releases, and industry mentions in real time, all in one place.

Structure Therapeutics (Structure)

Clinical-stage biopharmaceutical company developing oral small molecule therapeutics

structuretx.com

Headquarters: South San Francisco, United States
Founded year: 2017
Company type: Public company
Number of employees: 200–260
Industry: Pharmaceuticals

Last updated October 5

Latest news about Structure Therapeutics (Structure)

In short: Structure reported positive 72-week aleniglipron results as it dosed the first Phase 3 patients.

Company announcements

October 5 Structure

Structure presents aleniglipron trial data

The team shared positive 72-week results for the chronic weight management therapy at the EASD conference in Milan.

September 8 Structure

Structure Therapeutics reports positive clinical data for weight loss drugs

The company shared results from trials of ACCG-2671 and aleniglipron. Aleniglipron achieved up to 16.2% body weight loss. Phase 3 trials are ongoing.

August 6 Structure

Structure Therapeutics reports second quarter 2026 results and highlights

First patients dosed in Phase 3 ACCOMPLISH program; John Berrios appointed CCO; $1.3 billion cash expected to fund operations through 2028.

June 17 Structure

Structure announces promising Phase 2b aleniglipron data

Data showed up to 16.2% weight loss, no plateau, and low discontinuation; Phase 3 on track for Q3 2026.

Media coverage

September 22 Yahoo Finance

Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data - Structure Therapeutics (NASDAQ

Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss...

Never miss news about Structure

Track Structure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Structure competitors & trending companies

Browse news for competitors to Structure and other trending companies.